The use of chemical double-mutant cycles in biomolecular recognition studies: application to HCV NS3 protease inhibitors.
Kawai
Stephen H
SH
Department of Chemistry, Boehringer Ingelheim (Canada) Ltd., 2100, rue Cunard, Laval, Québec, Canada.
Bailey
Murray D
MD
Halmos
Ted
T
Forgione
Pat
P
Laplante
Steven R
SR
Llinàs-Brunet
Montse
M
Naud
Julie
J
Goudreau
Natalie
N
D000998:Antiviral Agents / Q000494:pharmacology*; D020134:Catalytic Domain; D002626:Chemistry, Pharmaceutical / Q000379:methods; D015195:Drug Design; D017353:Gene Deletion; D005998:Glycine / Q000737:chemistry; D016174:Hepacivirus / Q000378:metabolism*; D020128:Inhibitory Concentration 50; D008968:Molecular Conformation; D009154:Mutation; D010455:Peptides / Q000737:chemistry; D017434:Protein Structure, Tertiary; D013329:Structure-Activity Relationship; D013816:Thermodynamics; D017361:Viral Nonstructural Proteins / Q000235:genetics* / Q000378:metabolism*; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
D000998:Antiviral Agents; D005998:Glycine; D010455:Peptides; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases